Dashboard
1
Flat results in Mar 26
- OPERATING PROFIT(Q) Lowest at CNY 21.57 MM
- OPERATING PROFIT MARGIN(Q) Lowest at 27.52 %
- PRE-TAX PROFIT(Q) Lowest at CNY 23.53 MM
2
With ROE of 13.27%, it has a expensive valuation with a 0.83 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 680 Million (Small Cap)
6.00
NA
1.53%
-0.37
13.27%
0.83
Revenue and Profits:
Net Sales:
78 Million
(Quarterly Results - Mar 2026)
Net Profit:
21 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-26.87%
0%
-26.87%
6 Months
-35.08%
0%
-35.08%
1 Year
-21.77%
0%
-21.77%
2 Years
14.82%
0%
14.82%
3 Years
5.81%
0%
5.81%
4 Years
14.85%
0%
14.85%
5 Years
0%
0%
0.0%
Medprin Regenerative Medical Technologies Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
23.89%
EBIT Growth (5y)
47.20%
EBIT to Interest (avg)
35.56
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.41
Tax Ratio
14.29%
Dividend Payout Ratio
41.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.56%
ROE (avg)
8.17%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.83
EV to EBIT
3.54
EV to EBITDA
2.96
EV to Capital Employed
0.73
EV to Sales
1.02
PEG Ratio
0.28
Dividend Yield
1.53%
ROCE (Latest)
20.66%
ROE (Latest)
13.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
78.40
72.30
8.44%
Operating Profit (PBDIT) excl Other Income
21.60
31.40
-31.21%
Interest
0.00
0.00
Exceptional Items
0.20
-0.60
133.33%
Consolidate Net Profit
20.70
24.20
-14.46%
Operating Profit Margin (Excl OI)
275.20%
335.00%
-5.98%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 8.44% vs 26.40% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -14.46% vs 62.42% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
364.60
275.70
32.25%
Operating Profit (PBDIT) excl Other Income
138.50
102.50
35.12%
Interest
0.30
1.20
-75.00%
Exceptional Items
-2.00
-0.30
-566.67%
Consolidate Net Profit
113.10
78.90
43.35%
Operating Profit Margin (Excl OI)
302.90%
270.60%
3.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 32.25% vs 20.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 43.35% vs 92.91% in Dec 2024
About Medprin Regenerative Medical Technologies Co., Ltd. 
Medprin Regenerative Medical Technologies Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






